The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 07, 2017

Filed:

Feb. 03, 2016
Applicant:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Samuel J. Asirvatham, Rochester, MN (US);

Arshad Jahangir, Rochester, MN (US);

Bernard B. C. Lim, Rochester, MN (US);

Kalpathi L. Venkatachalam, Jacksonville Beach, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 18/10 (2006.01); A61B 18/12 (2006.01); A61B 18/14 (2006.01); A61B 18/08 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61M 25/00 (2006.01); A61N 1/20 (2006.01);
U.S. Cl.
CPC ...
A61B 18/10 (2013.01); A61B 18/082 (2013.01); A61B 18/1206 (2013.01); A61B 18/1233 (2013.01); A61B 18/1492 (2013.01); A61B 2017/00575 (2013.01); A61B 2018/0041 (2013.01); A61B 2018/0075 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00446 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2218/002 (2013.01); A61M 25/0071 (2013.01); A61N 1/205 (2013.01);
Abstract

Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.


Find Patent Forward Citations

Asirvatham, Samuel. (2017). Controlling coagulum formation (U.S. Patent No. 9585708). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9585708

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…